Clinical Trials
Women's Cancer Care of Seattle is committed to offering women state of the art treatment, including participation in clinical trials. The following is a list of clinical trials that are actively enrolling, and available in the infusion suite at Women's Cancer Care of Seattle or North West Hospital (Last updated 6/20/2011). There are new studies opening frequently, please do not hesitate to contact our office with any questions or for an updated list.
A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab (NSC#7044865, IND #7921) followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal and fallopian tube cancer.
http://www.cancer.gov/clinicaltrials/search/view?cdrid=546714&version=HealthProfessional&protocolsearchid=9584752 GOG0086P
A three arm randomized phase II study of paclitaxel/carboplatin/bevacizumab(NSC #704865, IND #7921), paclitaxel/carboplatin/temsirolimus (NSC #683864, IND#61010), and ixabepilone (NSC#710428 IND # 59699)/carboplatin/bevacizumab as initial thermeasurable stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer.
http://www.cancer.gov/clinicaltrials/search/view?cdrid=654472&version=HealthProfessional&protocolsearchid=9604374
A Phase III Trial of Pelvic Radiation Therapy versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma.
http://www.cancer.gov/clinicaltrials/search/view?cdrid=629591&version=HealthProfessional&protocolsearchid=9585501 GOG0252
Phase III Clinical Trial of Bevacizumab with IV versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma http://www.cancer.gov/clinicaltrials/search/view?cdrid=650601&version=HealthProfessional&protocolsearchid=9584752 GOG0258
A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma.
http://www.cancer.gov/clinicaltrials/search/view?cdrid=649079&version=HealthProfessional&protocolsearchid=9604410 GOG0260
A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (IND 110072).
http://www.cancer.gov/clinicaltrials/search/view?cdrid=641202&version=HealthProfessional&protocolsearchid=9585450 GOG0261
A Randomized Phase III trial of Paclitaxel plus Carboplatin versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary.
http://www.cancer.gov/clinicaltrials/search/view?cdrid=651458&version=HealthProfessional&protocolsearchid=9585450 GOG0262
A Randomized Phase III Trial of Every-3-Weeks Paclitaxel versus Dose Dense Weekly Paclitaxel in Combination with Carboplatin with or without Concurrent and Consolidation Bevacizumab (NSC #704865, IND #7921) in the Treatment of Primary Stage III or IV Epitlial Ovarian, Peritoneal or Fallopian Tube Cancer.
http://www.cancer.gov/clinicaltrials/search/view?cdrid=681448&version=HealthProfessional&protocolsearchid=9584752#ContactInfo_CDR0000681448 GOG0268
A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: 683864, IND #61010)in Combination with Carboplatin and Paclitaxel followed by Temsirolimus Consolidation as First-line Therapy in the Treatment of Clear Cell Carcinoma of the Ovary.
http://www.cancer.gov/clinicaltrials/search/view?cdrid=684262&version=HealthProfessional&protocolsearchid=9585450 GOG0724
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic RT With or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy (RTOG # 0724) (Heidi J Gray).
http://www.cancer.gov/clinicaltrials/search/view?cdrid=654709&version=HealthProfessional&protocolsearchid=9604412
GOG0212
A randomized phase III trial of maintenance chemotherapy comparing 12 monthly cycles of single agent paclitaxel or CT2103 (IND#70177) versus no treatment until documented relapse in women with advanced ovarian, primary peritoneal or fallopian tube cancer who achieve a complete clinical response to primary platinum/taxane therapy.
http://www.cancer.gov/clinicaltrials/search/view?cdrid=422427&version=HealthProfessional&protocolsearchid=9585450
A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab (NSC#7044865, IND #7921) followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal and fallopian tube cancer.
http://www.cancer.gov/clinicaltrials/search/view?cdrid=546714&version=HealthProfessional&protocolsearchid=9584752 GOG0086P
A three arm randomized phase II study of paclitaxel/carboplatin/bevacizumab(NSC #704865, IND #7921), paclitaxel/carboplatin/temsirolimus (NSC #683864, IND#61010), and ixabepilone (NSC#710428 IND # 59699)/carboplatin/bevacizumab as initial thermeasurable stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer.
http://www.cancer.gov/clinicaltrials/search/view?cdrid=654472&version=HealthProfessional&protocolsearchid=9604374
GOG0229J
A Phase II Evaluation of Cediranib (RECENTIN; AZD2171) in the Treatment of Recurrent or Persistent Endometrial Cancer.
http://www.cancer.gov/clinicaltrials/search/view?cdrid=674008&version=HealthProfessional&protocolsearchid=9585497
A Phase III Trial of Pelvic Radiation Therapy versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma.
http://www.cancer.gov/clinicaltrials/search/view?cdrid=629591&version=HealthProfessional&protocolsearchid=9585501 GOG0252
Phase III Clinical Trial of Bevacizumab with IV versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma http://www.cancer.gov/clinicaltrials/search/view?cdrid=650601&version=HealthProfessional&protocolsearchid=9584752 GOG0258
A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma.
http://www.cancer.gov/clinicaltrials/search/view?cdrid=649079&version=HealthProfessional&protocolsearchid=9604410 GOG0260
A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (IND 110072).
http://www.cancer.gov/clinicaltrials/search/view?cdrid=641202&version=HealthProfessional&protocolsearchid=9585450 GOG0261
A Randomized Phase III trial of Paclitaxel plus Carboplatin versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary.
http://www.cancer.gov/clinicaltrials/search/view?cdrid=651458&version=HealthProfessional&protocolsearchid=9585450 GOG0262
A Randomized Phase III Trial of Every-3-Weeks Paclitaxel versus Dose Dense Weekly Paclitaxel in Combination with Carboplatin with or without Concurrent and Consolidation Bevacizumab (NSC #704865, IND #7921) in the Treatment of Primary Stage III or IV Epitlial Ovarian, Peritoneal or Fallopian Tube Cancer.
http://www.cancer.gov/clinicaltrials/search/view?cdrid=681448&version=HealthProfessional&protocolsearchid=9584752#ContactInfo_CDR0000681448 GOG0268
A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: 683864, IND #61010)in Combination with Carboplatin and Paclitaxel followed by Temsirolimus Consolidation as First-line Therapy in the Treatment of Clear Cell Carcinoma of the Ovary.
http://www.cancer.gov/clinicaltrials/search/view?cdrid=684262&version=HealthProfessional&protocolsearchid=9585450 GOG0724
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic RT With or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy (RTOG # 0724) (Heidi J Gray).
http://www.cancer.gov/clinicaltrials/search/view?cdrid=654709&version=HealthProfessional&protocolsearchid=9604412